|1.||Zhang, Quanbin: 11 articles (01/2015 - 06/2003)|
|2.||Letourneur, Didier: 9 articles (01/2015 - 10/2002)|
|3.||Louedec, Liliane: 7 articles (01/2015 - 04/2003)|
|4.||Nakano, Takahisa: 6 articles (10/2015 - 05/2003)|
|5.||Maruyama, Hiroko: 6 articles (10/2015 - 05/2003)|
|6.||Michel, Jean-Baptiste: 6 articles (01/2015 - 10/2002)|
|7.||Lee, Boo-Yong: 6 articles (12/2012 - 01/2010)|
|8.||Tamauchi, Hidekazu: 5 articles (10/2015 - 05/2003)|
|9.||Zhang, Hong: 5 articles (09/2015 - 06/2003)|
|10.||Hou, Lin: 5 articles (06/2015 - 01/2012)|
03/01/1997 - "2. In the present study we have assessed the effects of fucoidin on eosinophil function in vitro and eosinophil accumulation at sites of inflammation in guinea-pig skin. "
10/01/2015 - "These data indicate that Mekabu fucoidan is an effective suppressor of inflammation in an ultraviolet B-irradiated mouse model. "
01/01/2015 - "Colon and spleen weight in mice treated with oral fucoidan was also significantly lower, indicating reduced inflammation and oedema. "
10/01/2012 - "To examine the effect of fucoidan treatment on inflammation-mediated dopaminergic neuronal damage and its potential mechanisms. "
06/01/2012 - "Therefore, it is suggested that fucoidan blocks infiltration of inflammatory cells, while CT extract inhibits activation of the cells, and that their combinational treatment could be a promising candidate for the relief of various types of inflammation."
11/01/2015 - "The primary objective of this study was to determine whether a natural antioxidant, fucoidan, could protect MSCs from ischemia-induced apoptosis in vitro and in vivo. "
11/01/2001 - "The objective of this study was to examine whether a decrease in neutrophil-mediated tissue injury using Fucoidin, a nontoxic neutrophil rolling inhibitor, would improve flap survival in an island flap model after ischemia-reperfusion. "
11/01/2015 - "In a murine hindlimb ischemia model, transplanted fucoidan-treated MSCs showed significantly enhanced cell survival and proliferation in ischemic tissues. "
11/01/2015 - "Fucoidan protects mesenchymal stem cells against oxidative stress and enhances vascular regeneration in a murine hindlimb ischemia model."
07/01/2015 - "Fucoidan could improve critical limb ischemia by promoting monocyte recruitment. "
04/01/2002 - "We investigated the efficacy of selectin blockade in a selective (monoclonal antibody RMP-1) and nonselective (Fucoidin) manner in pulmonary reperfusion injury. "
11/01/2015 - "Fucoidan reduces inflammatory response in a rat model of hepatic ischemia-reperfusion injury."
01/01/2013 - "Low molecular weight fucoidan against renal ischemia-reperfusion injury via inhibition of the MAPK signaling pathway."
03/01/2001 - "Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat."
11/01/2001 - "Protective effect of fucoidin (a neutrophil rolling inhibitor) on ischemia reperfusion injury: experimental study in rat epigastric island flaps."
|4.||Diabetic Nephropathies (Diabetic Nephropathy)
04/01/2015 - "Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-κB signaling pathway in vivo and in vitro."
01/01/2015 - "Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes."
04/01/2015 - "However, to date and to the best of our knowledge, pathological studies on the effects of fucoidan against diabetic nephropathy (DN) related to spontaneous diabetes have not been carried out. "
06/01/2014 - "The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy."
|5.||Body Weight (Weight, Body)
12/01/2008 - "A significant improvement of survival was observed by pretreatment with fucoidan at 100 mg/kg body weight. "
03/01/2011 - "After 3 weeks, fucoidan treatment improved left ventricular ejection fraction (79.04 ± 2.81 vs 65.94% ± 3.22%; P < .01 vs EAM-saline) with a reduced ratio of heart weight to body weight (4.016 ± 0.239 vs 4.975 ± 0.252 mg/g; P < .05 vs EAM-saline) in EAM. "
06/01/2014 - "Fucoidan treatment increased the body weight, food intake and serum protein levels, it decreases the level of hepatic markers. "
01/01/2014 - "The fucoidan supplementation group had significantly decreased body-weight gain, food efficiency ratio and relative liver and epididymal fat mass compared with the HFD group. "
02/15/2012 - "The fucoidan derivatives were administered at dose of 50 and 150 mg/kg body weight. "
|7.||Transforming Growth Factor beta (TGF-beta)
|8.||Tissue Inhibitor of Metalloproteinase-1
|9.||Interleukin-6 (Interleukin 6)
|10.||Non-alcoholic Fatty Liver Disease